LVH is a determinant of left atrial size and remodelling, and it would be expected that aggressive blood pressure control should prevent AF occurring in patients with diabetes. Angiotensin converting enzyme inhibitors (ACE inhibitors) do seem to prevent AF in hypertension supporting this hypothesis. A large cohort study, L’Allier et al. (2004), of eight million people on a database showed a reduced incidence of AF in patients on ACE inhibitors with hypertension [45]. By contrast the GISSI-AF study found that the angiotensin receptor blocker (ARB’s) valsartan did not reduce the incidence of AF in patients who before recruitment had two or more documented episodes of AF [46]. The important point here is that GISSI-AF recruited patients who had already had episodes of AF whereas in the L’Allier et al. (2004) study, the use of ACE inhibitors was restricted to patients with no previous history of AF. Interestingly in GISSI-AF, there was a reduced incidence of AF in the patients with diabetes subgroup but this was not significant (p = 0.11).

It is more conclusive that angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blocker (ARB’s) reduce the incidence of new onset AF in heart failure. Heart failure is linked to diabetes due to the reasons discussed previously. There are three main meta-analysis published in this area [47-49] . A metaanalysis by Kalus et al. (2006) of four clinical trials reports resulting effect of renin angiotensin system blockade in reducing new onset AF [47]. All four studies included patients with left ventricular dysfunction and showed a reduction in new onset AF in patients treated with ACE inhibitors or ARB’s. Anand et al. (2006) analysed nine randomised control trials and found that the use of ACE inhibitors and ARB’s across the trials showed a 18% risk reduction in the onset of new AF, but most importantly there was a 43% risk reduction in the subset of patients with heart failure [48]. Jibrini et al. (2008) included 11 randomised trials and included patients with heart failure, myocardial infarction and hypertension [49]. They found that treatment with ACE inhibitors or ARB’s reduced the relative risk for the development of new onset AF by 23% in hypertension, 11% in post myocardial infarction patients and by 32% in heart failure patients. These three meta-analyses of the major trials are the most compelling evidence for the use of ACE inhibitors and ARB’s to prevent new onset AF in patients with impaired left ventricular function. None of these trials published sub-group analysis of patients with diabetes.

A final discussion point is the use of thiazolidinediones. A case report from Greece has described two patients with type 2 diabetes who had an improvement in paroxysmal AF with rosiglitazone [50]. There is some evidence that thiazolidinediones reduce C reactive protein levels and inhibit oxidative stress [51,52] . It could be that thiazolidinediones with their pleitropic properties affect atrial remodelling [50]. However, thiazolidinediones are controversial in their links to heart failure and ischaemic heart disease, which may limit their potential use to prevent AF.


AF is one of the most common cardiac arrhythmias, and seems to be more common amongst people with diabetes. AF has a significant impact on morbidity and mortality, and in particular increases the long term risk of stroke. The reasons for AF being more common in patients with diabetes remain unclear. The specific combination of AF and diabetes is an under researched area that needs further research. Thiazolidinediones may prevent AF but at this stage the evidence for this is limited to theory and case reports. ACE inhibitors and ARB’s have shown promise in preventing new onset AF especially in patients with heart failure. Although the evidence for ACE inhibitors and ARBs preventing AF in diabetes is sparse, it is reasonable to presume they do so, although many patients with diabetes will have alternative indications for them anyway e.g. hypertension or microalbuminuria. Our review article highlights the need for more research into AF prevention and treatment in diabetes.


  1. Lloyd-Jones, D.M., Wang, T.J., Leip, E.P., Larson, M.G., Levy, D., Vasan, R.S., et al. (2004) Lifetime risk for development of atrial fibrillation: The Framingham heart study. Circulation, 110, 1042-1046. doi:10.1161/01.CIR.0000140263.20897.42
  2. Stewart, S., Murphy, N.F., Walker, A., McGuire, A. and McMurray, J.J. (2004) Cost of an emerging epidemic: An economic analysis of atrial fibrillation in the UK. Heart, 90, 286-292. doi:10.1136/hrt.2002.008748
  3. Benjamin, E., Wolf, P., D’Agostino, R., Silbershatz, H., Kannel, W. and Levy, D. (1998) Impact of atrial fibrillation on the risk of death: The Framingham heart study. Circulation, 98, 946-952. doi:10.1161/01.CIR.98.10.946
  4. Stewart, S., Hart, C.L., Hole, D.J. and McMurray, J.J. (2002) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. American Journal of Medicine, 113, 359-364. doi:10.1016/S0002-9343(02)01236-6
  5. Sugishita, K., Shiono, E., Sugiyama, T. and Ashida, T. (2003) Diabetes influences the cardiac symptoms related to atrial fibrillation. Circulation Journal, 67, 835-888. doi:10.1253/circj.67.835
  6. Gage, B.F., van Walraven, C., Pearce, L., Hart, R.G., Koudstaal, P.J., Boode, B.S.P., et al. (2004) Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin. Circulation, 110, 2287-2292.
  7. Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W. and Radford, M.J. (2001) Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. Journal of the American Medicine Association, 285, 2864-2870.
  8. Wilhelmsen, L., Rosengren, A. and Lappas, G. (2001) Hospitalizations for atrial fibrillation in the general male population: Morbidity and risk factors. Journal of Internal Medicine, 250, 382-389. doi:10.1046/j.1365-2796.2001.00902.x
  9. Movahed, M., Hashemzadeh, M. and Jamal, M. (2005) Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. International Journal of Cardiology, 105, 315- 321. doi:10.1016/j.ijcard.2005.02.050
  10. Nichols, G.A., Reinier, K. and Chugh, S.S. (2009) Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care, 32, 1851- 1856. doi:10.2337/dc09-0939
  11. Aksnes, T., Schmieder, R., Kjeldsen, S., Ghani, S., Hua, T. and Julius, S. (2008) Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the value trial). American Journal of Cardiology, 101, 634-638. doi:10.1016/j.amjcard.2007.10.025
  12. Benjamin, E.J, Wolf, P.A., D’Agostino, R.B., Silbershatz, H., Kannel, W.B. and Levy, D. (1998) Impact of atrial fibrillation on the risk of death: The Framingham heart study. Circulation, 98, 946-952.
  13. Ostgren, C.J., Merlo, J., Rastam, L. and Lindblad, U. (2004) Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes, Obesity and Metabolism, 6, 367-374. doi:10.1111/j.1462-8902.2004.00358.x
  14. Psaty, B.M., Manolio, T.A., Kuller, L.H., Kronmal, R.A, Cushman, M., Fried, L.P., et al. (1997) Incidence of and risk factors for atrial fibrillation in older adults. Circulation, 96, 2455-2461. doi:10.1161/01.CIR.96.7.2455
  15. Johansen, O., Brustad, E., Enger, S. and Tveit, A. (2008) Prevalence of abnormal glucose metabolism in atrial fibrillation: A case control study in 75-year old subjects. Cardiovascular Diabetology, 7, 28. doi:10.1186/1475-2840-7-28
  16. Stritzke, J., Markus, M.R.P., Duderstadt, S., Lieb, W., Luchner, A., Döring, A., et al. (2009) The aging process of the heart: Obesity is the main risk factor for left atrial enlargement during aging: The MONICA/KORA (monitoring of trends and determinations in cardiovascular disease/cooperative research in the region of Augsburg) study. Journal of the American College of Cardiology, 54, 1982-1989. doi:10.1016/j.jacc.2009.07.034
  17. Wasada, T., Katsumori, K., Hasumi, S., Kasanuki, H., Arii, H., Saeki, A., et al. (1995) Association of sick sinus syndrome with hyperinsulinemia and insulin resistance in patients with non-insulin-dependent diabetes mellitus: Report of four cases. Internal Medicine, 34, 1174-1177. doi:10.2169/internalmedicine.34.1174
  18. Gandhi, G., Nuttall, G., Abel, M., Mullany, C., Schaff, H., Williams, B., et al. (2005) Intraoperative hyperglycemia and perioperative outcomes in cardiac surgery patients. Mayo Clinic Proceedings, 80, 862-866. doi:10.4065/80.7.862
  19. Lazar, H.L., Chipkin, S.R., Fitzgerald, C.A., Bao, Y., Cabral, H. and Apstein, C.S. (2004) Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation, 109, 1497-502. doi:10.1161/01.CIR.0000121747.71054.79
  20. Rutter, M.K., Parise, H., Benjamin, E.J., Levy, D., Larson, M.G., Meigs, J.B., et al. (2003) Impact of glucose intolerance and insulin resistance on cardiac structure and function: Sex-related differences in the Framingham heart study. Circulation, 107, 448-454.
  21. Lind, L., Berne, C., Andren, B. and Lithell, H. (1996) Relationship between diastolic hypertension and myocardial morphology and function in elderly males with diabetes mellitus. Diabetologia, 39, 1603-1606. doi:10.1007/s001250050621
  22. Sundstrom, J., Lind, L., Nystrom, N., Zethelius, B., Andren, B., Hales, C.N., et al. (2000) Left Ventricular concentric remodeling rather than left ventricular hypertrophy is related to the insulin resistance syndrome in elderly men. Circulation, 101, 2595-2600.
  23. Palmieri, V., Bella, J.N., Arnett, D.K., Liu, J.E., Oberman, A., Schuck, M.-Y., et al. (2001) Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects: Hypertension genetic epidemiology network (HyperGEN) Study. Circulation, 103, 102-107.
  24. Galvan, A.Q., Galetta, F., Natali, A., Muscelli, E., Sironi, A.M., Cini, G., et al. (2000) Insulin resistance and hyperinsulinemia: No independent relation to left ventricular mass in humans. Circulation, 102, 2233-2238.
  25. Uusitupa, M., Siitonen, O., Pyorala, K., Mustonen, J., Voutilainen, E., Hersio, K., et al. (1987) Relationship of blood pressure and left ventricular mass to serum insulin levels in newly diagnosed non-insulin-dependent (type 2) diabetic patients and in non-diabetic subjects. Diabetes Research, 4, 19-25.
  26. Verdecchia, P., Reboldi, G., Schillaci, G., Borgioni, C., Ciucci, A., Telera, M.P., et al. (1999) Circulating insulin and insulin growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation, 100, 1802-1807.
  27. Young, M.E., McNulty, P. and Taegtmeyer, H. (2002) Adaptation and Maladaptation of the heart in diabetes: part II: Potential mechanisms. Circulation, 105, 1861- 1870.
  28. Collier, A., Matthews, D.M., Young, R.J. and Clarke, B.F. (1987) Transient atrial fibrillation precipitated by hypoglycaemia: Two case reports. Postgraduate Medical Journal, 63, 895-897. doi:10.1136/pgmj.63.744.895
  29. Odeh, M., Oliven, A. and Bassan, H. (1990) Transient atrial fibrillation precipitated by hypoglycemia. Annals of Emergency Medicine, 19, 565-567. doi:10.1016/S0196-0644(05)82191-2
  30. Baxter, M.A., Garewal, C., Jordan, R., Wright, A.D. and Nattrass, M. (1990) Hypoglycaemia and atrial fibrillation. Postgraduate Medical Journal, 66, 981. doi:10.1136/pgmj.66.781.981
  31. Lip, G.Y. and Varughese, G.I. (2005) Diabetes mellitus and atrial fibrillation: Perspectives on epidemiological and pathophysiological links. International Journal of Cardiology 105, 319-321. doi:10.1016/j.ijcard.2005.03.003
  32. Pollock, G., Brady, W.J., Jr., Hargarten, S., DeSilvey, D. and Carner, C.T. (1996) Hypoglycemia manifested by sinus bradycardia: A report of three cases. Academic Emergency Medicine, 3, 700-707. doi:10.1111/j.1553-2712.1996.tb03495.x
  33. Gill, G.V., Woodward, A., Casson, I.F. and Weston, P.J. (2009) Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes—The “dead in bed” syndrome revisited. Diabetologia, 52, 42-45. doi:10.1007/s00125-008-1177-7
  34. Marques, J.L., George, E., Peacey, S.R., Harris, N.D., Macdonald, I.A., Cochrane, T., et al. (1997) Altered ventricular repolarization during hypoglycaemia in patients with diabetes. Diabetic Medicine, 14, 648-654. doi:10.1002/(SICI)1096-9136(199708)14:8<648::AID-DIA418>3.0.CO;2-1
  35. Robinson, R.T., Harris, N.D., Ireland, R.H., Macdonald, I.A. and Heller, S.R. (2004) Changes in cardiac repolarization during clinical episodes of nocturnal hypoglycaemia in adults with Type 1 diabetes. Diabetologia, 47, 312-315. doi:10.1007/s00125-003-1292-4
  36. (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Archives of Internal Medicine, 154, 1449-1157. doi:10.1001/archinte.1994.00420130036007
  37. Laakso, M. (1999) Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes, 48, 937-942.
  38. Jaffar, A.R. and Assad, M. (2003) Current concepts of cardiovascular diseases in diabetes mellitus. International Journal of Cardiology, 89, 123-134. doi:10.1016/S0167-5273(02)00510-7
  39. Nesto, R.W. (2004) Correlation between cardiovascular disease and diabetes mellitus: Current concepts. American Journal of Medicine, 116, 11S-22S.
  40. Kannel, W.B. (1985) Lipids, diabetes, and coronary heart disease: Insights from the Framingham study. American Heart Journal, 110, 1100-1107. doi:10.1016/0002-8703(85)90224-8
  41. Milicevic, Z., Raz, I., Beattie, S.D., Campaigne, B.N., Sarwat, S., Gromniak, E., et al. (2008) Natural history of cardiovascular disease in patients with diabetes: Role of hyperglycemia. Diabetes Care, 31, S155-S160.
  42. Goraya, T.Y., Leibson, C.L., Palumbo, P.J., Weston, S.A., Killian, J.M., Pfeifer, E.A., et al. (2002) Coronary atherosclerosis in diabetes mellitus: A population-based autopsy study. Journal of the American College of Cardiology, 40, 946-953. doi:10.1016/S0735-1097(02)02065-X
  43. Hansson, L., Zanchetti, A., Carruthers S.G., Dahlof, B., Elmfeldt, D., Julius, S., et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 351, 1755-1762. doi:10.1016/S0140-6736(98)04311-6
  44. Cushman, W.C., Evans, G.W., Byington, R.P., Goff, D.C., Jr., Grimm, R.H., Jr., Cutler, J.A., et al. (1575) Effects of intensive blood-pressure control in type 2 diabetes mellitus. The New England Journal of Medicine, 362, 1575- 1585.
  45. L’Allier, P.L., Ducharme, A., Keller, P.F., Yu, H., Guertin, M.C. and Tardif, J.C. (2004) Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. Journal of the American College of Cardiology, 44, 159- 164. doi:10.1016/j.jacc.2004.03.056
  46. Disertori, M., Latini, R., Barlera, S., Franzosi, M.G., Staszewsky, L., Maggioni, A.P., et al. (2009) Valsartan for prevention of recurrent atrial fibrillation. The New England Journal of Medicine, 360, 1606-1617. doi:10.1056/NEJMoa0805710
  47. Kalus, J.S., Coleman, C.I. and White, C.M. (2006) The impact of suppressing the renin-angiotensin system on atrial fibrillation. The Journal of Clinical Pharmacology, 46, 21-28. doi:10.1177/0091270005283284
  48. Anand, K., Mooss, A.N., Hee, T.T. and Mohiuddin, S.M. (2006) Meta-analysis: Inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. American Heart Journal, 152, 217-222. doi:10.1016/j.ahj.2006.01.007
  49. Jibrini, M.B., Molnar, J. and Arora, R.R. (2008) Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: A systematic review and metaanalysis. The American Journal of Therapeutics, 15, 36- 43. doi:10.1097/MJT.0b013e31804beb59
  50. Korantzopoulos, P., Kokkoris, S., Kountouris, E., Protopsaltis, I., Siogas, K. and Melidonis, A. (2008) Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy. International Journal of Cardiology, 125, e51-e53. doi:10.1016/j.ijcard.2006.12.063
  51. Qayyum, R. and Adomaityte, J. (2006) Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels. American Journal of Cardiology, 97, 655-658. doi:10.1016/j.amjcard.2005.09.105
  52. Da Ros, R., Assaloni, R. and Ceriello, A. (2004) The preventive anti-oxidant action of thiazolidinediones: A new therapeutic prospect in diabetes and insulin resistance. Diabetic Medicine, 21, 1249-1252. doi:10.1111/j.1464-5491.2004.01312.x


AF                      Atrial fibrillation;

ACCORD             Action to Control Cardiovascular Risk in Diabetes trial;

ACE                   Angiotensin converting enzyme;

ARB                   Angiotensin receptor blocker;

TIA                   Transient ischaemic attack;

HOT                  Hypertension Optimal Treatment trial;

GISSI-AF           Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-Atrial                         Fibrillation trial.


*Declaration of competing interests: nothing to declare.

Journal Menu >>